N

Neuren Pharmaceuticals
NEU

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
A$2.09B
EV
A$1.86B
Shares Outstanding
126.95M
Beta
1.71

Wall Street View

Analyst Rating
BUY
Analyst Target Price
A$24.87
P/E 2025E
92.77x
P/Revenue 2025E
33.35x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Neuren Pharmaceuticals Limited

gainify

N

Neuren Pharmaceuticals Limited

NEU

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of a...

Sector

Healthcare

Industry

Biotechnology

CEO

Pilcher, Jonathan

Employees

8

IPO Date

2005-02-01

Headquarters

697 Burke Road, Suite 201, Camberwell, Victoria, 3124, Australia

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.